Galectin Therapeutics Inc. Stock Prediction and Forecast [GALT]

AI-generated source summary

Galectin Therapeutics (GALT) currently holds a 'Hold/Accumulate' rank with a score of 0.336, downgraded from a 'Buy' recommendation. Over the past 25 days, the stock has shown a gain of 9.01%, averaging 0.36% daily. In the short term, GALT is within a robust upward trend. The 3-month trend points to a potential change of 34.47%, with possible returns ranging from 25.85% to 58.33%. Our 12-month analysis forecasts a projected change of 163.16%, with returns ranging from 47.19% to 207.48%, suggesting a future price range between $7.65 and $15.99. The last trading day saw the stock close at $5.20, experiencing an 18.27% fluctuation between a low of $5.20 and a high of $6.15. The opening price was $5.40. GALT is currently 20.61% below its 52-week high of $6.55 and 45.21% below its all-time high of $9.49 from June 2018. The company has actively reported 2024 financials and quarterly updates, presenting NAVIGATE data at key liver conferences. Market reaction has been volatile, with significant selling post-topline results, though technical oversold signals and analyst revisions sparked mid-September momentum. While the short-term outlook could be influenced by conference visibility and clinical readouts, the long-term trajectory depends on belapeptin's clinical benefits and regulatory clarity. General ratings include 'Strong Sell' for cash flow, return on asset, dividend earnings, P/E, and price-to-book, with 'Return On Equity' rated as 'Strong Buy'. Technical signals indicate a 'Sell' from the short-term Moving Average and a 3-month MACD, but a 'Buy' from the long-term Moving Average and certain crossovers. A pivot top sell signal was issued on November 3rd, leading to a 13.33% decline. The stock's current price of $5.20 faces resistance at $5.37 and support at $5.10, with a weekly volatility of 11.34%, assessing the risk as medium. The P/E ratio is negative at -8.18, indicating current losses. The upcoming Q3 2025 earnings report on November 13th, with consensus estimates at -$0.11, could influence future prices. The suggested stop-loss is $4.89, representing a 6.04% decrease.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   11 Nov 2025, 04:01 UTC

   The analyst published the original source item.

2. First prediction resolved

   12 Nov 2025, 14:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   12 Nov 2025, 14:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:11 UTC

   Tahlil Plus began monitoring the extracted predictions.